LGVN
USDLongeveron Inc. Class A Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$0.820
High
$0.820
Low
$0.800
Volume
0.38M
Company Fundamentals
Market Cap
16.8M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.95M
Exchange
NCM
Currency
USD
52-Week Range
Related News
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions,
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHSFull enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II)
Related Stocks
TFINP
Triumph Financial Inc. Depositary Shares Each Representing a 1/40th Interest in a Share of 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock
KTOS
Kratos Defense & Security Solutions Inc.
SER
Serina Therapeutics Inc.
TELA
TELA Bio Inc.
ROAD
Construction Partners Inc.
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.